Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cilo Cybin HoldingsJSE:CCC 7 EV-to-EBIT is -0.80 as of Aug. 02, 2026. GuruFocus rates JSE:CCC with a GF Score™ of 7/100. The stock has 1 warning sign investors should review. Among 691 Drug Manufacturers companies, Cilo Cybin Holdings ranks worse than 144717.66% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cilo Cybin Holdings's Enterprise Value for the quarter that ended in Sep. 2025 was R1,085.33 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cilo Cybin Holdings's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was R-214.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cilo Cybin Holdings EV-to-EBIT Related Terms
Cilo Cybin Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Cilo Cybin Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cilo Cybin Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cilo Cybin Holdings EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cilo Cybin Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cilo Cybin Holdings's EV-to-EBIT falls into.
Cilo Cybin Holdings's current Enterprise Value is R172.09 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cilo Cybin Holdings's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was R-214.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cilo Cybin Holdings (JSE:CCC) has a EV-to-EBIT of -0.80 as of Aug. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cilo Cybin Holdings and its competitors. According to the industry distribution chart, Cilo Cybin Holdings ranks #999999 out of 691 companies in the Drug Manufacturers industry.
Is Cilo Cybin Holdings' EV-to-EBIT too high?
Cilo Cybin Holdings' current EV-to-EBIT is -0.80. Based on the distribution chart, Cilo Cybin Holdings ranks #999999 out of 691 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cilo Cybin Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Cilo Cybin Holdings' EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cilo Cybin Holdings ranks #999999 out of 691 companies for EV-to-EBIT. This places Cilo Cybin Holdings in the lower half of its industry. The industry median EV-to-EBIT is 15.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.69, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cilo Cybin Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cilo Cybin Holdings's current EV-to-EBIT is -0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cilo Cybin Holdings stock overvalued right now?
Cilo Cybin Holdings (JSE:CCC) has a current EV-to-EBIT of -0.80. The current EV-to-EBIT is -0.80. Cilo Cybin Holdings' overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cilo Cybin Holdings (JSE:CCC), the current EV-to-EBIT is -0.80 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cilo Cybin Holdings Ltd is engaged in identifying viable investments in Biotech, Biohacking and Pharmaceutical businesses. It offers products and services in the medical cannabis sector.
7GF Score
Get the complete analysis for JSE:CCC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:CCC has been successfully added to your 
